Haematology Oncology

Duval/CIBMTR Score for AML Transplanted in Relapse or Primary Induction Failure

Predicts 3-year overall survival after myeloablative allogeneic stem cell transplant for AML not in remission (relapse or primary induction failure) — Duval 2010, CIBMTR data.

Score interpretation

Duval 0 — 3-Year OS ~42% 0

Score 0: 3-year overall survival 42% after transplant with active AML (Duval 2010).

→ Transplant in active disease can give long-term survival in selected patients — plan HSCT with the transplant centre if otherwise eligible.

Duval 1 — 3-Year OS ~28% 1

Score 1: 3-year overall survival 28%.

→ HSCT can be considered; discuss expected benefit and risks with the transplant team and the patient.

Duval 2 — 3-Year OS ~15% 2

Score 2: 3-year overall survival 15%.

→ HSCT may still be considered; clinical trial participation; careful counselling about expected outcome.

Duval ≥ 3 — 3-Year OS ~6% 3–6

Score 3 or more: 3-year overall survival 6%.

→ Poor expected survival with transplant in active disease — counsel carefully; clinical trial preferred; goals-of-care discussion.

Interpretation bands for the Duval AML. Apply clinical judgement and local guidance.

References

Duval M et al. Hematopoietic Stem-Cell Transplantation for Acute Leukemia in Relapse or Primary Induction Failure. J Clin Oncol. 2010;28(23):3730-3738.

Curated clinical cross-links plus same-class fallbacks.

Calculators

Drugs

Pathways

Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.

Score interpretation

References

Related